Home

Phil Skolnick

CIK 1358116 · Chief Scientific Officer · last filed 2023-03-03

Phil Skolnick is a Chief Scientific Officer who has filed 34 SEC Form 4 insider transactions across 1 company since 2018. The most recent filing, for OPNT, was dated Mar 3, 2023. Across all open-market trades the lifetime net is −$2.1M, making them a net seller over the disclosed history. 6 SEC filings were submitted jointly with DOV PHARMACEUTICAL INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

1

Total Filings

34

Lifetime Open-Market Net

-$2.11M

Filer Profile

Reported Address
C/O DOV PHARMACEUTICAL, INC.
433 HACKENSACK AVENUE
HACKENSACK, NJ 07601
Related Filers
DOV PHARMACEUTICAL INC — 6 joint filings, latest 2008-05-23
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
OPIANT PHARMACEUTICALS, INC. (OPNT) Delisted Chief Scientific Officer 11,736 $20.65 $242.3K -$2.11M 29 2023-03-03

Recent Filings

34 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2023-03-03 OPIANT PHARMACEUTICALS, INC. (OPNT) Delisted Mixed −21,548 -$471.0K EDGAR
2023-01-31 OPIANT PHARMACEUTICALS, INC. (OPNT) Delisted Sell (S) −480 -$9.7K EDGAR
2023-01-09 OPIANT PHARMACEUTICALS, INC. (OPNT) Delisted Sell (S) −369 -$7.5K EDGAR
2023-01-05 OPIANT PHARMACEUTICALS, INC. (OPNT) Delisted Sell (S) −1,421 -$28.7K EDGAR
2022-07-15 OPIANT PHARMACEUTICALS, INC. (OPNT) Delisted Sell (S) −627 -$7.4K EDGAR
2022-06-29 OPIANT PHARMACEUTICALS, INC. (OPNT) Delisted Grant (A) +2,000 $0 EDGAR
2022-01-27 OPIANT PHARMACEUTICALS, INC. (OPNT) Delisted Sell (S) −1,518 -$39.8K EDGAR
2022-01-12 OPIANT PHARMACEUTICALS, INC. (OPNT) Delisted Sell (S) −385 -$11.7K EDGAR
2022-01-05 OPIANT PHARMACEUTICALS, INC. (OPNT) Delisted Grant (A) +12,000 $0 EDGAR
2021-01-27 OPIANT PHARMACEUTICALS, INC. (OPNT) Delisted Grant (A) +8,198 $0 EDGAR
Showing 1–10 of 34
Page 1 of 4
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.